Last reviewed · How we verify

NCT04894500: ICARUS

ICIS in Burn Patients Compared to Other Inflammatory Markers

Completed Last updated 7 January 2026
What this trial tests

trial testing Flow fluorescence cytometry in Infection, Bacterial in 97 participants. Completed in 31 October 2024.

Timeline
1 April 2021
Primary endpoint
30 June 2024
31 October 2024

Quick facts

Lead sponsorCharles University, Czech Republic
StatusCompleted
Study typeOBSERVATIONAL
Enrollment97
Start date1 April 2021
Primary completion30 June 2024
Estimated completion31 October 2024
Sites1 location across Czechia

Drugs / interventions tested

Conditions studied

Sponsor

Charles University, Czech Republic

Who can join

Adults 6 Months to 100, any sex, with Infection, Bacterial or Burns. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The current markers of inflammation that govern antibiotic treatment have their significant limitations, especially in patients with burns. According to previously published data, the newly proposed marker of infectious inflammation, the Intensive Care Infection Score (ICIS), appears to be a suitable diagnostic tool in distinguishing between inflammation of infectious and non-infectious origin in these patients. The other advantage is its low price. This study aims to compare ICIS with other used indicators of inflammation in patients with burns both children and adults.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Early identification of infectious complications in pediatric burn patients: a prospective cohort study.
    Bakalář B, Zajíček R, Frejlach D, Adámková V, et al · · 2026 · PMID 42002740 · DOI 10.1186/s12887-026-06867-7

Verify or expand the search:

Other recruiting trials for Infection, Bacterial

Currently open trials in the same condition.

Other Charles University, Czech Republic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04894500.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing